Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Structural determinants of potassium channel blockade and drug-induced arrhythmias.

Wehrens XH.

Handb Exp Pharmacol. 2006;(171):123-57. Review.

PMID:
16610343
2.

K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation.

Clancy CE, Kurokawa J, Tateyama M, Wehrens XH, Kass RS.

Annu Rev Pharmacol Toxicol. 2003;43:441-61. Epub 2002 Jan 10. Review.

PMID:
12540747
3.
4.

Studying cardiac arrhythmias in the mouse--a reasonable model for probing mechanisms?

Nerbonne JM.

Trends Cardiovasc Med. 2004 Apr;14(3):83-93. Review.

PMID:
15121155
5.

Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart.

Finley MR, Li Y, Hua F, Lillich J, Mitchell KE, Ganta S, Gilmour RF Jr, Freeman LC.

Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H126-38.

6.

Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.

Witchel HJ, Hancox JC.

Clin Exp Pharmacol Physiol. 2000 Oct;27(10):753-66. Review.

PMID:
11022966
7.
8.

I(Kr): the hERG channel.

Tseng GN.

J Mol Cell Cardiol. 2001 May;33(5):835-49. Review.

PMID:
11343409
9.

Molecular determinants of high-affinity drug binding to HERG channels.

Mitcheson JS, Perry MD.

Curr Opin Drug Discov Devel. 2003 Sep;6(5):667-74. Review.

PMID:
14579516
10.

Structural determinants and biophysical properties of HERG and KCNQ1 channel gating.

Tristani-Firouzi M, Sanguinetti MC.

J Mol Cell Cardiol. 2003 Jan;35(1):27-35. Review.

PMID:
12623297
11.

Rb+ efflux through functional activation of cardiac KCNQ1/minK channels by the benzodiazepine R-L3 (L-364,373).

Jow F, Tseng E, Maddox T, Shen R, Kowal D, Dunlop J, Mekonnen B, Wang K.

Assay Drug Dev Technol. 2006 Aug;4(4):443-50.

PMID:
16945016
12.

Effects of the antifungal antibiotic clotrimazole on human cardiac repolarization potassium currents.

Tian M, Dong MQ, Chiu SW, Lau CP, Li GR.

Br J Pharmacol. 2006 Feb;147(3):289-97.

13.

Modulation of HERG potassium channel function by drug action.

Thomas D, Karle CA, Kiehn J.

Ann Med. 2004;36 Suppl 1:41-6.

PMID:
15176423
14.

Pharmacology of cardiac potassium channels.

Tamargo J, Caballero R, Gómez R, Valenzuela C, Delpón E.

Cardiovasc Res. 2004 Apr 1;62(1):9-33. Review.

PMID:
15023549
15.

Subcellular localization of the delayed rectifier K(+) channels KCNQ1 and ERG1 in the rat heart.

Rasmussen HB, Møller M, Knaus HG, Jensen BS, Olesen SP, Jørgensen NK.

Am J Physiol Heart Circ Physiol. 2004 Apr;286(4):H1300-9. Epub 2003 Dec 11.

16.

Inhibition of cardiac delayed rectifier K+ current by overexpression of the long-QT syndrome HERG G628S mutation in transgenic mice.

Babij P, Askew GR, Nieuwenhuijsen B, Su CM, Bridal TR, Jow B, Argentieri TM, Kulik J, DeGennaro LJ, Spinelli W, Colatsky TJ.

Circ Res. 1998 Sep 21;83(6):668-78.

17.

Repolarization of the cardiac action potential. Does an increase in repolarization capacity constitute a new anti-arrhythmic principle?

Grunnet M.

Acta Physiol (Oxf). 2010 Feb;198 Suppl 676:1-48. doi: 10.1111/j.1748-1716.2009.02072.x.

PMID:
20132149
18.

Pharmacology of cardiac potassium channels.

Li GR, Dong MQ.

Adv Pharmacol. 2010;59:93-134. doi: 10.1016/S1054-3589(10)59004-5. Review.

PMID:
20933200
19.

Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia.

Sanguinetti MC.

Ann N Y Acad Sci. 1999 Apr 30;868:406-13. Review.

PMID:
10414310
20.

[Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by the HERG expression system].

Chachin M, Kurachi Y.

Nihon Yakurigaku Zasshi. 2002 Jun;119(6):345-51. Japanese.

PMID:
12089906

Supplemental Content

Support Center